Clinical Research

View data and clinical studies backing Cerefolin Brain Wellness™* for Mild Cognitive Impairment (MCI).

Targeted Nutrition Helps Lower Elevated Homocysteine Levels

L-methylfolate, methylcobalamin, and N-acetyl-l-cysteine efficiently decrease homocysteine levels, mitigating vascular damage and brain atrophy linked to cognitive decline. Compared to those with no HHcy and not taking Cerefolin Brain Wellness™:^1-3*

Hippocampal atrophy slowed by 4.25 times^1*
Cortical atrophy slowed by 11.2 times ^1*

The relationship between plasma homocysteine and cognitive decline warrants preventive strategies to preserve cognitive function^17,18

See Product Details

Homocysteine Elevating Factors

Elevated Homocysteine can lead to cognitive impairment.

Demographics ^19-23

Increased Age
Male
Menopause
Race

Vitamin Deficiencies²⁰

Folate
B12

Diseases^20,24,25

Chronic renal failure
Diabetes
Hypothyroidism

Drugs^16,26-30

Anticonvulsants
Levodopa
Metformin
Methotrexate
Nitrous oxide
Oral contraceptives
Proton pump inhibitors

Lifestyle^24,31,32

Alcohol abuse
Methionine-rich animal protein diet
Physical inactivity
Tobacco smoking

Genetic Alterations²⁰

Methylenetetrahydrofolate
reductase (MTHFR)

The Predictive Value of Homocysteine

In the Framingham Study of homocysteine and cognitive performance, they found:

A statistically significant inverse association between elevated homocysteine (Hcy) and cognitive performance in individuals 60 years of age or older.⁸
Early intervention may be important because the inverse association between Hcy and cognitive performance was observed beyond middle age.⁸

Proven to Slow the Change in Predicted Memory Performance

Starting Cerefolin Brain Wellness™* early can help delay cognitive decline in tasks of memory and constructional praxis. Longer-term treatment may be associated with significantly slower decline compared to those not on therapy. Improvements were seen in sequencing, response inhibition, and constructional praxis in a follow-up study.^2,3*

Disclaimers

Cerefolin Brain Wellness™ is a targeted nutrition product for the clinical dietary management of mild cognitive impairment with hyperhomocysteinemia and is specially formulated to meet the distinctive nutritional requirements for this condition. Use under medical supervision.

§ Images don’t portray actual consumers and are for illustration purposes only.

|| Testimonials based on experience with CerefolinNAC®*.

* Cerefolin Brain Wellness™, formerly known and studied as CerefolinNAC®, is the same trusted and effective product that is now free from major allergens (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, sesame and soy), dyes, and colorants.

† By submitting this information, I hereby give Alfasigma USA, Inc. authorization to release, reproduce, use or distribute information about me, in original or modified form, for promotional and educational purposes in all forms of media, including print, broadcast or Internet. This information may include my medical information if I choose to submit any. I understand my information may be shared with a third party working on Alfasigma USA, Inc.’s behalf for promotional or educational purposes. I also understand that I may be contacted by this third party or Alfasigma USA, Inc. for more information.

^†† This product should be taken under medical supervision, and you should consult your healthcare provider before taking this for mild cognitive impairment.

References

Shankle WR, et al. J Alzheimer’s Dis. 2016 Oct 4;54(3):1073-1084
Shankle WR, et al. J Aging Res Clin Prac. 2013
Hara J, et al. Nutr Health Aging. 2015
Alfasigma USA. Data on File. PLUS Program: Patient Survey Results 2012. USA
Data on file. Support data 2019-2024. Alfasigma USA.
Chan A, et al. J Nutr Health Aging 2008;12(4):252-61.
de Jager CA. et al. Int J Geriatr Psychiatry. 2012 Jun:27(6):592-600.
Merrill E, et al. Am. J. Epidemiol. 2005 Oct;162(7):644-53.
Altern Med Rev 2000 Oct;5(5):467-71.
de Jager CA. Neurobiol Aging 2014;35(suppl 2):535-9.
Atkuri KR, et al. Curr Opin Pharmacol. 2007. 2007
N-acetylcysteine. Monograph. Alt Med Rev. 2000
Antoniades C, et al. Circulation. 2006.
Calderón-Ospina CA, et al. CNS Neurosci Ther. 2020.
Kimura, A.M et al. Alzheimer’s Dement. 2021.
Rogers JD, et al. Arch Neurol. 2003 Jan;60(1):59-64.
Smith AD, et al. J Alzheimer’s Dis.
Seshadri S, et al. N Engl J Med. 2002.
Yao Y, et al. J Geriatr Cardiol. 2017.
Diaz-Arrastia R, et al. Arch Neurol. 2000.
Keller, A.C., et al. J. Appl. Physiol. 2019.
Zhu Z, et al. Climacteric. 2020.
Estrada, D.A. et al. Am. J. Hematol. 2001.
Luzzi S, et al. Biomedicines. 2022.
Diekman, M. J. M., et al. Clin. Endocrinol. (Oxf) 2001.
Paknahad Z, et al. Int J Prev Med. 2012.
Desouza, C, et al. Drugs. 2002.
P. S. Myles et al. Br. J. Anaesth. 2008.
Fallah S, et al. J Clin Lab Anal. 2012.
Lerman, et al. AJMS., 2022.
Troen AM, et al. Proc Natl Acad Sci U S A. 2003.
Haj Mouhamed D, et al. Clin Chem Lab Med. 2011.

Clinical Research

Targeted Nutrition Helps Lower Elevated Homocysteine Levels

Homocysteine Elevating Factors

Demographics 19-23

Vitamin Deficiencies20

Diseases20,24,25

Drugs16,26-30

Lifestyle24,31,32

Genetic Alterations20